BAC BV, the leading provider of antibody-based affinity purification technology together with Life Technologies Corporation has announced the launch of a range of POROS®CaptureSelect® affinity columns. By combining BAC’s CaptureSelect affinity ligand technology with Life Technologies’ POROS resin, the companies now offer a platform for high speed, high performance product-specific process monitoring for a broad range of biomolecules.

The POROS CaptureSelectline of analytical columns, which offer precise quantitation of important classes of biomolecules in minutes, are the first products resulting from the companies’ strategic collaboration announced in June 2011.

The initial product line includes:

• POROSCaptureSelectLC-kappa and POROSCaptureSelectLC-lambda; for the analysis of human antibodies and antibody fragments containing either a kappa or a lambda light chain.
• POROSCaptureSelectIgG-Fc; for the detection of any human IgG subclass (even IgG3) in the presence of IgG from other sources (e.g. bovine).
• POROSCaptureSelectIgM; for the analysis of human, mouse and rat IgM.
• POROSCaptureSelectHSA; for the analysis of HSA-fusion proteins (specific for human serum albumin in the presence of albumin from other species).

The affinity resins are offered in four different column sizes (0.1-7.9 ml column volumes) providing optimal flexibility to the end user. These products are now available for purchase through Life Technologies’ website: http://www.lifetechnologies.com/poros/captureselect

Christine Gebski, Head of Life Technologies POROS business stated: “We are excited to be able to combine the unique specificity provided by the BAC CaptureSelect® ligands on our high performance POROS® 20 µm resin. We believe the addition of these products to our existing Affinity Chromatography Column line will unlock the same benefits of rapid, automatable quantitation or small scale purification for many other classes of biological molecules providing enabling technology to our customers.”

“The launch of these columns exemplifies the success of this strategic collaboration in making these media available to the wider research community in a short timeframe,” commented Dr. Laurens Sierkstra, CEO of BAC, adding, “We look forward to developing additional innovative products in the future.”

—ENDS—

Notes to editors:

About Life Technologies Bioproduction

Life Technologies is a global leader in bioprocessing products that support the production of biologics-based therapeutics and vaccines from molecule to market, with leading brands such as Gibco® cell culture products and cell therapy systems; POROS® chromatography for process-scale bioseparations; and Applied Biosystems® SEQ rapid molecular methods for contaminant detection and identification. Our customized Gibco® media and cell line development services have been used by leading biotechnology and pharmaceutical companies worldwide to optimize the productivity of their production platforms. Please follow Life Technologies' Bioproduction business on Twitter at .

About Life Technologies Corporation

Life Technologies Corporation (NASDAQ: ) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: . Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

About BAC BV

BAC discovers, develops and manufactures separation and affinity purification products for use across the value chain of biopharmaceutical R&D and manufacturing. Based on BAC’s proprietary single-chain antibody technology called CaptureSelect^®, the products are suitable for the discovery, preclinical and clinical manufacturing of therapeutic proteins, including antibodies and antibody fragments. They enable a reduced time to market, increased purity and yield and an overall lower cost of goods for biopharmaceutical drug development. BAC BV was established in 1995 as a Unilever subsidiary and is collaborating with the leading life sciences vendors. Currently the Company employs 37 people with an R&D laboratory facility in Leiden and a state-of-the-art ISO 9001 certified manufacturing plant in Naarden, the Netherlands. For more information about BAC, visit , and for CaptureSelect^® products, visit

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.